Published in Philos Trans R Soc Lond B Biol Sci on April 29, 1999
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet (2004) 9.68
Antimalarial drug resistance. J Clin Invest (2004) 8.50
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J (2007) 4.85
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet (2007) 4.85
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov (2009) 4.00
History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev (2004) 3.40
Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother (2006) 3.10
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J (2009) 2.70
The de novo selection of drug-resistant malaria parasites. Proc Biol Sci (2003) 2.63
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci (2002) 2.20
Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol (2007) 2.18
The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infect Dis (2015) 1.89
A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS One (2008) 1.88
A pre-emptive strike against malaria's stealthy hepatic forms. Nat Rev Drug Discov (2009) 1.77
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol (2003) 1.55
Epidemiological models for the spread of anti-malarial resistance. Malar J (2003) 1.54
Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother (2003) 1.45
Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob Agents Chemother (2006) 1.43
Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med (2006) 1.42
Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther (2009) 1.41
Drug resistance and genetic mapping in Plasmodium falciparum. Curr Genet (2008) 1.36
Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem Pharmacol (2008) 1.35
cDNA sequences reveal considerable gene prediction inaccuracy in the Plasmodium falciparum genome. BMC Genomics (2007) 1.35
In vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger. Antimicrob Agents Chemother (2010) 1.34
Do patients adhere to over-the-counter artemisinin combination therapy for malaria? evidence from an intervention study in Uganda. Malar J (2012) 1.28
Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J (2014) 1.24
Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J (2010) 1.20
Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. PLoS One (2010) 1.19
Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread. Int J Antimicrob Agents (2013) 1.19
Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother (2002) 1.18
Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections. Eur J Clin Microbiol Infect Dis (2004) 1.17
Association of house spraying with suppressed levels of drug resistance in Zimbabwe. Malar J (2004) 1.16
Early parasitological response following artemisinin-containing regimens: a critical review of the literature. Malar J (2013) 1.14
Improving childhood malaria treatment and referral practices by training patent medicine vendors in rural south-east Nigeria. Malar J (2009) 1.14
In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar J (2007) 1.12
Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum. Proc Natl Acad Sci U S A (2000) 1.12
Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malar J (2008) 1.09
Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother (2004) 1.05
Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS One (2011) 1.04
In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob Agents Chemother (2002) 1.04
Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Antimicrob Agents Chemother (2011) 1.04
Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am J Trop Med Hyg (2010) 1.03
Challenges of drug-resistant malaria. Parasite (2014) 1.02
Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics. Antimicrob Agents Chemother (2000) 1.00
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med (2015) 0.99
Plasmodium falciparum: development of a transgenic line for screening antimalarials using firefly luciferase as the reporter. Exp Parasitol (2008) 0.98
How can natural products serve as a viable source of lead compounds for the development of new/novel anti-malarials? Malar J (2011) 0.96
Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis. Malar J (2012) 0.95
Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar J (2007) 0.95
Effect of combinations of marketed human anthelmintic drugs against Trichuris muris in vitro and in vivo. Parasit Vectors (2012) 0.94
Experimental evolution of resistance to artemisinin combination therapy results in amplification of the mdr1 gene in a rodent malaria parasite. PLoS One (2010) 0.94
A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. Ann Clin Microbiol Antimicrob (2006) 0.94
The antimalarial ferroquine: from bench to clinic. Parasite (2011) 0.93
Plasmodium falciparum: differential selection of drug resistance alleles in contiguous urban and peri-urban areas of Brazzaville, Republic of Congo. PLoS One (2011) 0.92
Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants. Trans R Soc Trop Med Hyg (2009) 0.92
Artemisinin combination therapy for malaria: beyond good efficacy. Clin Infect Dis (2009) 0.92
Resisting resistance: dealing with the irrepressible problem of malaria. Br J Clin Pharmacol (2006) 0.91
Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin. Antimicrob Agents Chemother (2013) 0.91
Drugs for malaria: something old, something new, something borrowed. F1000 Biol Rep (2011) 0.91
Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Antimicrob Agents Chemother (2007) 0.90
Chloroquine Resistant Plasmodium falciparum in Nigeria: Relationship between pfcrt and pfmdr1 Polymorphisms, In-Vitro Resistance and Treatment Outcome. Open Trop Med J (2008) 0.88
Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study. Malar J (2015) 0.86
Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats. Malar J (2009) 0.86
Trends in malaria morbidity following the introduction of artesunate plus amodiaquine combination in M'lomp village dispensary, south-western Senegal. Malar J (2008) 0.84
Artemisinin derivatives for treatment of uncomplicated Plasmodium falciparum malaria in Sudan: too early for too much hope. Parasitol Res (2009) 0.82
Design and evaluation of primaquine-artemisinin hybrids as a multistage antimalarial strategy. Antimicrob Agents Chemother (2011) 0.81
Drug resistance and in vitro susceptibility of Plasmodium falciparum in Thailand during 1988-2003. Korean J Parasitol (2009) 0.81
Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro. Antimicrob Agents Chemother (2004) 0.80
Combination chemotherapy against Clonorchis sinensis: experiments with artemether, artesunate, OZ78, praziquantel, and tribendimidine in a rat model. Antimicrob Agents Chemother (2009) 0.80
Performance and time to become negative after treatment of three malaria rapid diagnostic tests in low and high malaria transmission settings. Malar J (2016) 0.80
High efficacy of two artemisinin-based combinations: artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine for falciparum malaria in Yemen. Malar J (2015) 0.79
Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials. PLoS Negl Trop Dis (2011) 0.79
A Method for Amplicon Deep Sequencing of Drug Resistance Genes in Plasmodium falciparum Clinical Isolates from India. J Clin Microbiol (2016) 0.79
In Vitro Activities of Primaquine-Schizonticide Combinations on Asexual Blood Stages and Gametocytes of Plasmodium falciparum. Antimicrob Agents Chemother (2015) 0.79
Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa. Curr Drug Metab (2011) 0.79
Selection and reversal of Plasmodium berghei resistance in the mouse model following repeated high doses of artemether. Parasitol Res (2003) 0.78
The effect of intermittent preventive treatment on anti-malarial drug resistance spread in areas with population movement. Malar J (2014) 0.78
Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties. ACS Med Chem Lett (2013) 0.78
The impact of heterogeneous transmission on the establishment and spread of antimalarial drug resistance. J Theor Biol (2013) 0.78
Design and Synthesis of Novel Hybrid Molecules against Malaria. Int J Med Chem (2015) 0.77
The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children. Parasitol Res (2006) 0.77
In vitro potentiation of antibiotic activities by a catecholate iron chelator against chloroquine-resistant Plasmodium falciparum. Antimicrob Agents Chemother (2002) 0.77
The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: a systematic review and meta-analysis. Pathog Glob Health (2012) 0.77
Assessment of Markers of Antimalarial Drug Resistance in Plasmodium falciparum Isolates from Pregnant Women in Lagos, Nigeria. PLoS One (2016) 0.76
A systematic review of the efficacy of a single dose artemisinin-naphthoquine in treating uncomplicated malaria. Malar J (2015) 0.75
Interaction between rifampicin, amodiaquine and artemether in mice infected with chloroquine resistant Plasmodium berghei. Malar J (2014) 0.75
Combination therapy--a way to forestall artemisinin resistance and optimize uncomplicated malaria treatment. J Med Life (2015) 0.75
Factors associated with appropriate home management of uncomplicated malaria in children in Kassena-Nankana district of Ghana and implications for community case management of childhood illness: a cross-sectional study. BMC Public Health (2015) 0.75
In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali. Am J Trop Med Hyg (2016) 0.75
Bioeconomic analysis of child-targeted subsidies for artemisinin combination therapies: a cost-effectiveness analysis. J R Soc Interface (2015) 0.75
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. PLoS Med (2016) 0.75
Mathematical Modelling to Guide Drug Development for Malaria Elimination. Trends Parasitol (2016) 0.75
Highly active ozonides selected against drug resistant malaria. Mem Inst Oswaldo Cruz (2016) 0.75
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother (1997) 7.36
Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A (1988) 5.92
Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (1997) 5.07
Plasmodium vivax resistance to chloroquine? Lancet (1989) 4.51
Impact of chloroquine resistance on malaria mortality. C R Acad Sci III (1998) 4.41
Mating patterns in malaria parasite populations of Papua New Guinea. Science (1995) 4.40
Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell (1997) 3.98
Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet (1991) 3.72
Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A (1997) 3.48
Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci U S A (1994) 3.45
Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 3.40
Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg (1998) 3.39
Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg (1996) 3.36
Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem (1994) 3.34
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg (1991) 3.31
Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev (1996) 3.26
Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci U S A (1990) 3.24
Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol Biochem Parasitol (1993) 3.16
Preventing antimalarial drug resistance through combinations. Drug Resist Updat (1998) 3.11
Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol (1997) 2.88
The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother (1997) 2.84
Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg (1993) 2.76
Malaria disaster in Africa. Lancet (1998) 2.72
Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection. Am J Trop Med Hyg (1955) 2.71
Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother (1992) 2.63
The role of shops in the treatment and prevention of childhood malaria on the coast of Kenya. Trans R Soc Trop Med Hyg (1992) 2.60
Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens. Am J Trop Med Hyg (1996) 2.34
Multigenic drug resistance among inbred malaria parasites. Proc Biol Sci (1997) 2.34
Malarial haemozoin/beta-haematin supports haem polymerization in the absence of protein. Nature (1995) 2.30
A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans R Soc Trop Med Hyg (1986) 2.12
The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today (1997) 2.07
Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol (1995) 2.05
Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol (1992) 1.97
Antimalarial drugs and the mosquito transmission of Plasmodium. Int J Parasitol (1997) 1.92
Evidence for environmental modulation of gametocytogenesis in Plasmodium falciparum in continuous culture. Bull World Health Organ (1979) 1.91
Treatment of malaria: some considerations and limitations of the current methods of assessment. Trans R Soc Trop Med Hyg (1990) 1.91
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg (1996) 1.90
The mode of action and the mechanism of resistance to antimalarial drugs. Acta Trop (1994) 1.85
Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther (1993) 1.84
A model for the origins and spread of drug-resistant malaria. Parasitology (1997) 1.84
Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg (1996) 1.84
The treatment of Plasmodium falciparum infection with chloroquine, with a note on infectivity to mosquitoes of primaquine- and pyrimethamine-treated cases. Am J Hyg (1956) 1.83
The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. Trans R Soc Trop Med Hyg (1987) 1.76
The prevention of antimalarial drug resistance. Pharmacol Ther (1990) 1.61
Regulation of infectivity of Plasmodium to the mosquito vector. Adv Parasitol (1996) 1.59
Estimation of inbreeding coefficients from genotypic data on multiple alleles, and application to estimation of clonality in malaria parasites. Genet Res (1995) 1.55
The differing impact of chloroquine and pyrimethamine/sulfadoxine upon the infectivity of malaria species to the mosquito vector. Am J Trop Med Hyg (1998) 1.46
The evolution of multiple drug resistance in malaria parasites. Trans R Soc Trop Med Hyg (1998) 1.44
In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. J Infect Dis (1998) 1.26
Persistence of drug-resistant malaria parasites. Lancet (1978) 1.21
Population genetics of nonclonal, nonrandomly mating malaria parasites. Parasitol Today (1991) 1.15
The chemotherapy of rodent malaria XXXV. Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'. Ann Trop Med Parasitol (1984) 1.14
Derivation of highly mefloquine-resistant lines from Plasmodium falciparum in vitro. Am J Trop Med Hyg (1993) 1.06
Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Trans R Soc Trop Med Hyg (1988) 1.02
Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa. Trop Med Int Health (1998) 1.00
The mode of action of the antimalarial artemisinin and its derivatives. Gen Pharmacol (1996) 0.99
Current views on the mechanisms of resistance to quinoline-containing drugs in Plasmodium falciparum. Ann Trop Med Parasitol (1995) 0.97
In-vitro resistance of Plasmodium falciparum to qinghaosu derivatives in west Africa. Lancet (1994) 0.96
Costs and benefits of resistance against antimalarial drugs. Parasitol Today (1998) 0.94
Inverse correlation of sensitivity in vitro of Plasmodium falciparum to chloroquine and mefloquine in Ghana. Trans R Soc Trop Med Hyg (1995) 0.85